SHP2作为抗肿瘤治疗靶点的价值及其在肿瘤免疫治疗中的应用

doi:10.11904/j.issn.1002-3070.2022.06.005

摘要/Abstract

摘要： 包含Src同源2结构域的蛋白酪氨酸磷酸酶2(Src homology region 2-containing protein tyrosine phosphatase 2,SHP2)是目前唯一被证实具有促癌作用的细胞质蛋白酪氨酸磷酸酶,在多种恶性肿瘤中高表达。SHP2可以通过介导受体酪氨酸激酶(Receptor tyrosine kinase,RTK)下游的RAS/ERK、PI3K/Akt和JAK/STAT等信号通路促进肿瘤发生发展,影响肿瘤预后。同时,SHP2参与调控PD-1/PD-L1、CTLA-4、BLTA和TIGIT等免疫检查点信号通路,对于肿瘤微环境中各种免疫细胞都有重要的调节作用。靶向SHP2不仅可以通过抑制RTK下游信号通路,还可以通过改善免疫微环境治疗恶性肿瘤。因此,SHP2具有免疫与靶向双重治疗肿瘤的功能,作为抗肿瘤治疗的靶点展现出极高的潜能与价值。

关键词: 包含Src同源2结构域的蛋白酪氨酸磷酸酶2, 肿瘤, 肿瘤免疫微环境, 免疫治疗

Abstract: Src homology region 2-containing protein tyrosine phosphatase 2(SHP2)is the only cytoplasmic protein tyrosine phosphatase that has been confirmed to promote cancer.There are highly expressed in a variety of malignant tumors.SHP2 can promote tumor development and affect tumor prognosis by mediating RAS/ERK,PI3K/Akt,JAK/STAT and other signal pathways downstream of receptor tyrosine kinase(RTK).At the same time,SHP2 is involved in the regulation of immune checkpoint signaling pathways such as PD-1 / PD-L1,CTLA-4,BLTA and TIGIT,and plays an important role in regulating various immune cells in the tumor microenvironment.Targeting SHP2 can treat malignant tumors not only by inhibiting RTK downstream signaling pathways,but also by improving the immune microenvironment.Therefore,SHP2 has the function of dual treatment tumor by immunity and targeting,and it shows extremely high potential and value as a target for anti-tumor therapy.

Key words: Protein tyrosine phosphatase 2 containing Src homology 2 domain, Tumor, Tumor immune microenvironment, Immunotherapy

中图分类号:

张玥, 汪越, 魏嘉. SHP2作为抗肿瘤治疗靶点的价值及其在肿瘤免疫治疗中的应用[J]. 实用肿瘤学杂志, 2022, 36(6): 513-519.

ZHANG Yue, WANG Yue, WEI Jia. The value of SHP2 as an anti-tumor therapeutic target and its application in tumor immunotherapy[J]. Journal of Practical Oncology, 2022, 36(6): 513-519.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.06.005

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I6/513

参考文献

1 Chen H,Libring S,Ruddraraju KV,et al.SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer[J].Oncogene,2022,39(49):7166-7180.
2 Nagamura Y,Miyazaki M,Nagano Y,et al.SHP2 as a potential therapeutic target in diffuse-type gastric carcinoma addicted to receptor tyrosine kinase signaling[J].Cancers(Basel),2021,13(17):4309.
3 Lazzara MJ,Lane K,Chan R,et al.Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations[J].Cancer Res,2010,70(9):3843-3850.
4 Cao M,Gao D,Zhang N,et al.Shp2 expression is upregulated in cervical cancer,and Shp2 contributes to cell growth and migration and reduces sensitivity to cisplatin in cervical cancer cells[J].Pathol Res Pract,2019,215(11):152621.
5 Frankel T,Lanfranca MP,Zou WP.The role of tumor microenvironment in cancer immunotherapy[J].Adv Exp Med Biol,2017,1036:51-64.
6 Liu QQ,Qu J,Zhao MX,et al.Targeting SHP2 as a promising strategy for cancer immunotherapy[J].Pharmacol Res,2020,152:104595.
7 Huang WQ,Lin Q,Zhuang X,et al.Structure,function,and pathogenesis of SHP2 in developmental disorders and tumorigenesis[J].Curr Cancer Drug Targets,2014,14(6):567-588.
8 Hof P,Pluskey S,Dhe-Paganon S,et al.Crystal structure of the tyrosine phosphatase SHP2[J].Cell,1998,92(4):441-450.
9 Jia Z,Ye Q,Dinaut AN,et al.Structure of protein tyrosine phosphatase 1B in complex with inhibitors bearing two phosphotyrosine mimetics[J].J Med Chem,2001,44:4584-4594.
10 Miura K,Wakayama Y,Tanino M,et al.Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2 -regulated activation of extracellular signal-regulated kinase[J].Oncogene,2013,32(45):5292-5301.
11 胡中倩,张炽敏.蛋白酪氨酸磷酸酶SHP2基因及其与实体瘤关系[J].转化医学杂志,2013,2(2):113-116.
12 Liu FF,Yang XT,Geng MY,et al.Targeting ERK,an achilles′ heel of the MAPK pathway,in cancer therapy[J].Acta Pharm Sin B,2018,8(4):552-562.
13 Yuan XR,Bu H,Zhou JP,et al.Recent advances of SHP2 inhibitors in cancer therapy:current development and clinical application[J].J Med Chem,2020,63(20):11368-11396.
14 Liu C,Lu HY,W HY,et al.Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling[J].Clin Cancer Res,2021,27(1):342-354.
15 Ou SI,Koczywas M,Ulahannan S,et al.A12 the SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer:preliminary evaluation of a first-in-man phase 1 clinical trial[J].J Thorac Oncol,2020,15:15-16.
16 Fedele C,Li S,Teng KW,et al.SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling[J].J Exp Med,2021,218(1):e20201414.
17 Yuan Y,Fan YL,Gao ZC,et al.SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability via the PI3K/AKT/GSK3β signaling pathway[J].Cancer Biol Med,2020,17(3):707-725.
18 Zhang WJ,Chan RJ,Chen HY,et al.Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia[J].J Biol Chem,2009,284(33):22353-22363.
19 Kim M,Morales LD,Jang I,et al.Protein tyrosine phosphatases as potential regulators of STAT3 signaling[J].Int J Mol Sci,2018,19(9):2708.
20 Song YH,Zhao M,Zhang HQ,et al.Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials[J].Pharmacol Ther,2022,230:107966.
21 Zehender A,Huang J,Gyorfi AH,et al.The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis[J].Nat Commun,2018,9(1):3259.
22 Thommen DS,Schumacher TN.T cell dysfunction in cancer[J].Cancer Cell,2018,33(4):547-562.
23 Liu W,Guo WJ,Shen LH,et al.T lymphocyte SHP2-deficiency triggers anti-tumor immunity to inhibit colitis-associated cancer in mice[J].Oncotarget,2017,8(5):7586-7897.
24 Hosseinzadeh R,Feizisani F,Shomali N,et al.PD-1/PD-L1 blockade:prospectives for immunotherapy in cancer and autoimmunity[J].IUBMB Life,2021,73(11):1293-1306.
25 Xia LL,Liu YY,Wang Y.PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer:current status and future directions[J].Oncologist,2019,24(Suppl 1):31-41.
26 Carlino MS,Larkin J,Long GV.Immune checkpoint inhibitors in melanoma[J].Lancet,2021,398(10304):1002-1014.
27 Okosuka T,Takamatsu M,Kobayashi-Imanishi W,et al.Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2[J].J Exp Med,2012,209(6):1201-1217.
28 Xu XZ,Hou BW,Fulzele A,et al.PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2[J].J Cell Biol,2020,219(6):e201905085.
29 Zhao JL,Roberts A,Wang ZL,et al.Emerging role of PD-1 in the central nervous system and brain diseases[J].Neurosci Bull,2021,37(8):1188-1202.
30 Zhao MX,Guo WJ,Wu YY,et al.SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade[J].Acta Pharm Sin B,2019,9(2):304-315.
31 Schneider H,Dias SR,Hu H,et al.A regulatory role for cytoplasmic YVKM motif in CTLA-4 inhibition of TCR signaling[J].Eur J Immunol,2001,31(7):2042-2050.
32 Xu XZ,Masubuchi T,Cai QX,et al.Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors[J].Elife,2021,10:e74276.
33 Liu XG,Hou M,Liu Y.TIGIT,a novel therapeutic target for tumor immunotherapy[J].Immunol Invest,2017,46(2):172-182.
34 Boutilier AJ,Elsawa SF.Macrophage polarization states in the tumor microenvironment[J].Int J Mol Sci,2021,22(13):6995.
35 Wang L,Iorio C,Yan K,et al.A ERK/RSK-mediated negative feedback loop regulates M-CSF-evoked PI3K/AKT activation in macrophages[J].FASEB J,2018,32(2):875-887.
36 Li D,Xiong W,Wang YD,et al.SLAMF3 and SLAMF4 are immune checkpoints that constrain macrophage phagocytosis of hematopoietic tumors[J].Sci Immunol,2022,7(67):5501.
37 Gao J,Wu ZG,Zhao MX,et al.Allosteric inhibition reveals SHP2-mediated tumor immunosuppression in colon cancer by single-cell transcriptomics[J].Acta Pharm Sin B,2022,12(1):149-166.
38 Song H,Song JX,Cheng M,et al.METTL3-mediated m6A RNA methylation promotes the anti-tumour immunity of natural killer cells[J].Nat Commun,2021,12(1):5522.
39 Friederichs K,Schmitz J,Weissenbach M,et al.Interleukin-6-induced proliferation of pre-B cells mediated by receptor complexes lacking the SHP2/SOCS3 recruitment sites revisited[J].Eur J Biochem,2001,268(24):6401-6407.
40 Tang KH,Li S,Jamayran AK,et al.Combined inhibition of SHP2 and CXCR1/2 promotes antitumor T-cell response in NSCLC[J].Cancer Discov,2022,12(1):47-61.
41 Liu C,Lu HY,Wang HY,et al.Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling[J].Clin Cancer Res,2021,27(1):342-354.
42 Xu ZY,Guo CY,Ye QL,et al.Endothelial deletion of SHP2 suppresses tumor angiogenesis and promotes vascular normalization[J].Nat Commun,2021,12(1):6310.
43 Bard-Chapeau EA,Li S,Ding J,et al.Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis[J].Cancer Cell,2011,19(5):629-639.
44 Qi C,Han T,Tang H,et al.Shp2 inhibits proliferation of esophageal squamous cell cancer via dephosphorylation of stat3[J].Int J Mol Sci,2017,18(1):134.
45 Wei B,Xu LY,Guo WJ,et al.SHP2-mediated inhibition of DNA repair contributes to cGAS-STING activation and chemotherapeutic sensitivity in colon cancer[J].Cancer Res,2021,81(12):3215-3228.
46 Chen WS,Liang Y,Zong M,et al.Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment[J].Cell Rep,2021,37(6):109974.
47 Fedele C,Ran H,Diskin B,et al.SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models[J].Cancer Discov,2018,8(10):1237-1249.
48 Wong GS,Zhou J,Liu JB,et al.Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition[J].Nat Med,2018,24(7):968-977.

[1]	王嘉倍, 张运广, 刘连新. 免疫治疗联合分子靶向药物治疗中晚期肝细胞癌的临床疗效及安全性分析:一项单臂回顾性研究[J]. 实用肿瘤学杂志, 2022, 36(6): 489-494.
[2]	杨菊, 刘芹, 刘宝瑞, 魏嘉. 胃癌相关癌睾抗原筛选与免疫浸润分析[J]. 实用肿瘤学杂志, 2022, 36(6): 495-501.
[3]	巩芮宁, 任贺. 胰腺导管腺癌免疫治疗研究现状和展望[J]. 实用肿瘤学杂志, 2022, 36(6): 502-506.
[4]	曹文杰, 魏瑗, 邝栋明. 肿瘤浸润B细胞与免疫治疗[J]. 实用肿瘤学杂志, 2022, 36(6): 507-512.
[5]	程思远, 韩子翰, 郭晓欢, 沈琳, 彭智. 肠道菌群与肿瘤免疫治疗疗效及不良反应关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 520-525.
[6]	那睿思, 郭影, 时佳琪, 郑桐森. 小肠肿瘤罕见原因[J]. 实用肿瘤学杂志, 2022, 36(6): 526-530.
[7]	王馨艺, 路一平（综述, 孙峥嵘. m6A RNA甲基化修饰影响恶性肿瘤及肿瘤干细胞生物学特性的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 551-555.
[8]	张淑敏, 张弓. ILC2s在肿瘤免疫调控中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 566-569.
[9]	朱开彬, 贺长军, 陈澜涛, 孔祥龙, 赵苏, 徐世东. TAM通过PLGF/Flt-1和TGF-β1通路促进非小细胞肺癌生长和肿瘤血管异生的研究[J]. 实用肿瘤学杂志, 2022, 36(5): 391-397.
[10]	王钦, 刘军杰, 陆秀鑫, 吴雅菲, 张文皓. 基于铁死亡的纳米联合疗法在恶性肿瘤治疗中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 429-434.
[11]	黄永平, 李梦洁, 孙玉芳, 项涛. 细菌生物膜在肿瘤生物学进程及治疗应用中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 440-444.
[12]	何晓晴, 柯鹏, 张新友. BCL-2抑制剂在血液恶性肿瘤中的靶向治疗应用及作用机制[J]. 实用肿瘤学杂志, 2022, 36(5): 452-457.
[13]	李雄, 姜文凯, 郎泽昆, 芮少珍. 肿瘤相关中性粒细胞与胰腺癌关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 458-462.
[14]	李鑫林, 周金意, 韩仁强, 蔡波, 徐红, 韩颖颖. 2013—2017年南通市肺癌流行病学特征分析[J]. 实用肿瘤学杂志, 2022, 36(4): 304-309.
[15]	孙伟玲, 张明辉, 吴华星, 赵艳滨. 血清肿瘤标志物对肺癌患者支气管镜活检病理组织学分型的预测价值[J]. 实用肿瘤学杂志, 2022, 36(4): 316-322.